Protective effects of selective mineralocorticoid receptor antagonist against aortic aneurysm progression in a novel murine model

Abstract Background The optimal medical management to delay the progression of aortic aneurysms has not been fully clarified, and the only standard treatment at present is antihypertensive therapy. Previous studies have shown beneficial effects of selective mineralocorticoid receptor (MR) antagonist...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of surgical research 2013-11, Vol.185 (1), p.455-462
Main Authors: Kurobe, Hirotsugu, MD, PhD, Hirata, Yoichiro, MD, PhD, Matsuoka, Yuki, BS, Sugasawa, Noriko, BS, Higashida, Mayuko, MS, Nakayama, Taisuke, MD, Maxfield, Mark Webster, MD, Yoshida, Yasushi, PhD, Shimabukuro, Michio, MD, PhD, Kitagawa, Tetsuya, MD, PhD, Sata, Masataka, MD, PhD
Format: Article
Language:English
Subjects:
Animals
Aortic aneurysm
Aortic Aneurysm - drug therapy
Aortic Aneurysm - immunology
Aortic Aneurysm - pathology
Blood Pressure
Chemokine CCL2 - genetics
Disease Models, Animal
Disease Progression
Gene Expression - drug effects
Gene Expression - immunology
Interleukin-6 - genetics
Macrophages - drug effects
Macrophages - immunology
Male
Mice
Mice, Inbred C57BL
Mineralocorticoid Receptor Antagonists - pharmacology
MR antagonist
Preventive medicine
Spironolactone - analogs & derivatives
Spironolactone - pharmacology
Surgery
Tumor Necrosis Factor-alpha - genetics
Vasculitis - drug therapy
Vasculitis - immunology
Vasculitis - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The optimal medical management to delay the progression of aortic aneurysms has not been fully clarified, and the only standard treatment at present is antihypertensive therapy. Previous studies have shown beneficial effects of selective mineralocorticoid receptor (MR) antagonists on cardiovascular remodeling. The aim of the present study was to investigate the effect of a selective MR antagonist on aortic aneurysm progression. Methods Seven-week-old C57BL/6J male mice were administered with angiotensin II and β-aminopropionitrile for 4 weeks. The mice received either vehicle or eplerenone, a selective MR antagonist (100 mg/kg daily) every day by gavage, starting at 7 weeks of age. The production of inflammatory cytokines in cultures of high mobility group box-1–stimulated macrophages with or without a MR antagonist was also analyzed using an enzyme-linked immunosorbent assay. Results Although no differences were found in the peak systolic blood pressure between the experimental groups, the mice in the eplerenone group showed a significant reduction in aneurysm development. On histologic analysis, coarse and stretched elastic fibers were markedly improved in the aortic wall in the eplerenone group. Real-time polymerase chain reaction of both aortic wall and perivascular adipose tissue demonstrated the expression of tumor necrosis factor-α, interleukin-6, and matrix metalloproteinase-2 was significantly decreased in eplerenone group, and that of monocyte chemoattractant protein-1 in the aortic wall was also significantly decreased. Macrophage infiltration in the aortic wall and perivascular adipose tissue in the eplerenone group was also significantly decreased. The production of tumor necrosis factor-α and interleukin-6 in macrophage culture, which was stimulated by high mobility group box-1 and CpG oligodeoxynucleotides, was also significantly decreased in the eplerenone group. Conclusions Eprelenone suppressed aortic aneurysm progression through an anti-inflammatory effect. Thus, selective MR antagonists might be effective in preventing the progression of aortic aneurysms.
ISSN:0022-4804
1095-8673
DOI:10.1016/j.jss.2013.05.002